Press Release Source: Pluristem Therapeutics Inc. Pluristem Therapeutics to Present its Clinical Trial Plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference Tuesday February 19, 8:01 am ET NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI - News) (DAX:PJT), a leading bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and autoimmune disorders, announced today that it will present its clinical trial plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California, USA. The presentation will take place on February 19th at 1 pm Pacific Time and will be web-cast live (at http://wsw.com/webcast/roth16/psti/) and for 90 days following the presentation. ADVERTISEMENT Mr. Zami Aberman, Pluristem’s Chairman and CEO commented, “We are very glad to have the opportunity to present our cutting edge cell therapy technology and our clinical programs at the Roth Capital Partners 20th Annual OC Growth Stock Conference. We strongly believe that our PLX cells can revolutionize the treatment of hematological malignancies and peripheral artery disease (PAD) and be therapeutically beneficial to millions of people. The Company is moving forward with its clinical programs and expects to announce its progress with the FDA and the EMEA (the Federal Drug Administration and the European Medicines Agency). Our target is to start our clinical trials in humans during 2008.” About the Roth Capital Partners 20th Annual OC Growth Stock Conference Presented by ROTH Capital Partners February 18-21, 2008 @ The Ritz Carlton Laguna Niguel One Ritz-Carlton Drive Dana Point, California 92629 The Roth Capital Partners 20th Annual OC Growth Stock Conference will be held February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, California. The conference will consist of three focused days of presentations from over 300 small-cap companies. About Pluristem Pluristem Therapeutics Inc. is a company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first product, PLX-I, is directed at resolving the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB). Pluristem's products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta, a non-controversial source, and not from embryonic stem cells. The MSCs are expanded in the Company's proprietary PluriXTM 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are believed to be immune-privileged and immunosuppressive, hence protecting the recipient from immunological reactions that often accompany transplantation. Pluristem has offices in the USA with research and manufacturing facilities in Israel. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements in this release include that PLX cells can revolutionize the treatment of hematological malignancies and peripheral artery disease (PAD) and be therapeutically beneficial to millions of people; that the Company expects to announce its progress with the FDA and the EMEA; and that the Company’s target is to start clinical trials in humans during 2008. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. In addition, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission, including the Company’s latest annual report on form 10-KSB. For more information visit our website at www.pluristem.com, the content of which is not part of this press release. Contact: Pluristem Therapeutics Inc. William Prather, +1-303-883-4954 Sr. VP Corporate Development bill@pluristem.com or CEOcast Michael Wachs, +1-212-732-4300 mwachs@ceocast.com -------------------------------------------------------------------------------- Source: Pluristem Therapeutics Inc.